Engineered Tumor-Derived Extracellular Vesicles: Potentials in Cancer Immunotherapy

Exosomes are nano vesicles from the larger family named Extracellular Vesicle (EV)s which are released by various cells including tumor cells, mast cells, dendritic cells, B lymphocytes, neurons, adipocytes, endothelial cells, and epithelial cells. They are considerable messengers that can exchange proteins and genetic materials between the cells. Within the past decade, Tumor derived exosomes (TEX) have been emerged as important mediators in cancer initiation, progression and metastasis as well as host immune suppression and drug resistance. Although tumor derived exosomes consist of tumor antigens and several Heat Shock Proteins such as HSP70 and HSP90 to stimulate immune response against tumor cells, they contain inhibitory molecules like Fas ligand (Fas-L), Transforming Growth Factor Beta (TGF-β) and Prostaglandin E2 (PGE2) leading to decrease the cytotoxicity and establish immunosuppressive tumor microenvironment (TME). To bypass this problem and enhance immune response, some macromolecules such as miRNAs, HSPs and activatory ligands have been recognized as potent immune inducers that could be used as anti-tumor agents to construct a nano sized tumor vaccine. Here, we discussed emerging engineered exosomes as a novel therapeutic strategy and considered the associated challenges.

Abstract licence: CC BY

1. 7.

   Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA) · 2015

2. 13.

   The Roles of Tumor-Derived Exosomes in Cancer Pathogenesis · 2011

3. 15.

   Tumor-Derived Microvesicles Induce, Expand and Up-Regulate Biological Activities of Human Regulatory T Cells (Treg) · 2010

4. 23.

   Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects · 2005

5. 30.

   Prostate Tumor-Derived Exosomes Down-Regulate NKG2D Expression on Natural Killer Cells and CD8+ T Cells: Mechanism of Immune Evasion · 2014

35 more references, whose wording the paper’s licence keeps private.

• Current advance of nanotechnology in diagnosis and treatment for malignant tumors · 2024

• Extracellular vesicles: a rising star for therapeutics and drug delivery · 2023

• Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer · 2022

• Recent advances in overcoming barriers to cell‐based delivery systems for cancer immunotherapy · 2022

• The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer · 2022

• Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy · 2021

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.